Group 1 - The annual general meeting of Zhejiang Oriental Gene Biological Products Co., Ltd. was held on May 28, 2025, at the company's conference room in Anji County, Huzhou City, Zhejiang Province [2] - All resolutions presented at the meeting were approved without any objections [2] - The meeting was conducted in accordance with the Company Law, Securities Law, and the company's articles of association, with a combination of on-site and online voting [2][3] Group 2 - All current directors (7) and supervisors (3) attended the meeting, along with the company secretary and senior management [3] - The following non-cumulative voting proposals were approved: 2024 Board Work Report, 2024 Supervisory Board Work Report, 2024 Financial Settlement Report, 2024 Annual Profit Distribution Plan, 2024 Annual Report and Summary, 2025 Financial Budget Report, 2025 Director Remuneration Plan, 2025 Supervisor Remuneration Plan, and the proposal to reappoint the auditing firm for 2025 [4][5] - The meeting did not involve any special resolutions, and certain proposals required abstention from related shareholders [6] Group 3 - The meeting was witnessed by lawyers from Guohao Law Firm (Hangzhou), confirming that the meeting's procedures and results were legal and valid [7] - The company will file the meeting resolutions and legal opinions as required [9]

Group 1 - China Energy Construction won a major coal-fired power project with a bid amount of approximately 14.586 billion yuan, involving six 660 MW supercritical coal-fired generating units and supporting environmental facilities, with a total construction period of about 36.5 months [1] - Taiji Industry plans to repurchase company shares with a total amount not less than 1 billion yuan and not exceeding 1.2 billion yuan, with a maximum repurchase price of 10.38 yuan per share [1] - Youxun Technology won a project from State Grid with a bid amount of approximately 176 million yuan, accounting for 17.44% of the company's audited revenue for 2024 [2] Group 2 - Daili New Materials established an investment fund with a total subscribed capital of 163.3 million yuan, with Daili contributing 10 million yuan, accounting for 6.12% of the fund [4] - Wanyi Technology received a government subsidy of 2.3475 million yuan, which has been confirmed and classified according to relevant accounting standards [6] - Anke Biotech received a drug registration certificate for Acetate Atosiban Injection, which is used for treating preterm labor [7] Group 3 - Renfu Pharmaceutical received a drug registration certificate for Progesterone Soft Capsules, which are used to treat functional disorders caused by progesterone deficiency [9] - Linyang Energy is a recommended candidate for a major contract with State Grid, with a total expected bid amount of approximately 165 million yuan [11] - Hongtian Technology plans to invest 200 million to 300 million yuan to establish a wholly-owned subsidiary in Gansu Province [28] Group 4 - Hunan Xiang Electric received a total of 40 million yuan in government subsidies, which accounts for 16.07% of the company's audited net profit for 2024 [44] - Nengke Technology plans to repurchase shares with a total amount not less than 10 million yuan and not exceeding 20 million yuan, with a maximum repurchase price of 43.00 yuan per share [46] - Xiamen XGMA received 10 million yuan in historical debt repayment, which is expected to increase the company's net profit for 2025 by 3.186 million yuan [48]

Core Points - The company announced a cash dividend of 0.2 yuan per share, totaling 21,644,000 yuan based on a total share capital of 108,220,000 shares [1][2] - The profit distribution plan was approved at the annual shareholders' meeting on May 16, 2025, for the fiscal year 2024 [1] Distribution Plan - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the registration date [1] - The distribution will be executed through the clearing system of the China Securities Depository and Clearing Corporation, with specific procedures for shareholders who have completed designated trading [3][4] Taxation Details - For individual shareholders holding unrestricted shares for over one year, the dividend income is exempt from personal income tax, resulting in a net cash dividend of 0.2 yuan per share [5][6] - Shareholders holding shares for less than one year will have taxes calculated upon the transfer of shares, with the actual cash dividend remaining at 0.2 yuan per share until then [5] - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, leading to a net cash dividend of 0.18 yuan per share [7] - Other institutional investors will be responsible for their own tax payments, receiving a gross cash dividend of 0.2 yuan per share [8]

Group 1 - The stock of Sanofi (688336) closed at 58.90 yuan on May 27, with a significant increase of 15.31%, a turnover rate of 3.46%, and a trading volume of 1.204 billion yuan [2] - The stock was listed on the daily trading list due to its closing price increase of 15% [2] - The top five trading departments accounted for a total transaction amount of 223 million yuan, with a net buying amount of 657,000 yuan [2] Group 2 - The main capital inflow for the stock was 29.5876 million yuan on the same day [3] - Over the past six months, the stock has appeared on the trading list five times, with an average price increase of 14.11% the day after being listed and an average increase of 33.47% in the following five days [3] - The top buying departments included two institutional special seats, with buying amounts of 26.2829 million yuan and 18.1939 million yuan respectively [3]

Group 1 - The core point of the announcement is the adjustment of the conversion price for the company's convertible bonds "Kangtai Zhuan 2" from 15.82 CNY to 15.73 CNY per share, effective from June 6, 2025 [1][2] - The adjustment is based on the company's 2024 annual equity distribution plan, which includes a cash dividend of 0.90 CNY per 10 shares, with no stock dividends or capital reserve transfers [2] - The adjustment formula used for the conversion price is P1 = P0 - D, where P0 is the previous conversion price and D is the cash dividend per share [2] Group 2 - The company issued 20 million convertible bonds on July 15, 2021, under the code "Kangtai Zhuan 2" [1] - The adjustment of the conversion price is in accordance with relevant laws and regulations, as well as the terms outlined in the bond issuance prospectus [1][2] - The effective date for the new conversion price will be the day after the equity distribution, which is June 6, 2025 [2]

证券代码：300601 证券简称：康泰生物 公告编号：2025-050 债券代码：123119 债券简称：康泰转 2 深圳康泰生物制品股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股东大会审议通过利润分配方案情况 分派方案已经公司 2025 年 5 月 20 日召开的 2024 年度股东大会审议通过。2024 年度利润分配方案为：以 2024 年年度权益分派实施公告中确定的股权登记日当 日的总股本为基数，向全体股东每 10 股派 0.90 元（含税）现金红利，不送红股， 不以资本公积金转增股本。 事项发生变化。根据公司 2024 年度股东大会决议，本次权益分派以 2024 年年度 权益分派实施公告中确定的股权登记日当日的总股本为基数，无需调整分配比例， 公司按照分配比例不变的原则对分配总额进行调整。 原则一致。 二、本次实施的利润分配方案 公司 2024 年年度权益分派方案为：以 2024 年年度权益分派实施公告中确定 的股权登记日当日的总股本为基数，向全体股东每 10 股派 0.900000 元现金红利 （含税；扣税后，通过深股通持有股份 ...

Group 1 - The core viewpoint is that the pharmaceutical sector is gradually recovering, reflected in the performance of listed companies, despite limited overall index growth [1] - The manager emphasizes a balanced approach to investment, focusing on risk-reward ratios and aiming for excess returns relative to the pharmaceutical index over time [1] - The fund manager has a strong track record, with the fund achieving a return of 87.60% since inception, ranking first in its category for various time frames [1] Group 2 - The fund's investment scope includes various segments of the pharmaceutical and healthcare industry, such as chemical pharmaceuticals, traditional Chinese medicine, biological products, and medical services [2] - The top ten holdings of the fund are diversified across high-growth areas like innovative drugs and medical devices, which helps mitigate individual stock volatility while participating in overall industry growth [2] - The holdings are balanced, reducing the risk associated with any single stock and enhancing exposure to the sector's growth potential [2]

Group 1 - Guangdian Electric's wholly-owned subsidiary plans to sell 5.91% stake in Shanghai Winshun Electric Technology Co., Ltd. to Yapp Automotive Parts Co., Ltd. for 62.63 million yuan, aiming to optimize asset structure [1] - Anhui Natural Gas received approval for the registration of 500 million yuan short-term financing bonds and 600 million yuan medium-term notes, valid for two years [1] - Kirin Security received government subsidies totaling 6.48 million yuan, which are related to revenue [2] Group 2 - Junshi Biosciences received approval for two new indications for its self-developed drug, Oncorhynchus monoclonal antibody injection, targeting adult patients with heterozygous familial hypercholesterolemia and non-familial hypercholesterolemia [3] - China Resources Double Crane's subsidiary passed GMP compliance inspection for small and large volume injection production lines [4] - Nanjing Public Utilities' board approved the absorption and merger of its wholly-owned subsidiary, Nanjing Jinguang Industry Co., Ltd. [7] Group 3 - Boya Bio received drug registration certificate for human immunoglobulin (pH4) in the Dominican Republic, valid until August 12, 2029 [8] - Jizhi Co. announced that its controlling shareholder and actual controller committed not to reduce their shareholdings until December 31, 2025 [9] - Yuhua Tian won a bid for the integrated urban management project in Lanzhou City, with a total service subsidy of 353 million yuan [10] Group 4 - Anke Rui obtained five invention patent certificates related to various energy management and control technologies [11] - Kebo Da's wholly-owned subsidiary plans to acquire 100% of Czech IMI Company for approximately 9.43 million euros to enhance global production layout [13] - Yantian Port announced a cash dividend of 1.30 yuan per 10 shares, totaling 676 million yuan [14] Group 5 - Huawang Technology plans to distribute a cash dividend of 0.45 yuan per share and a capital reserve increase of 0.20 shares per share [15] - Kabe Yi established a wholly-owned subsidiary in Japan to enhance its business layout [16] - Dongcheng Pharmaceutical's subsidiary received approval for the marketing of sodium fluoride injection, a PET radiopharmaceutical [18] Group 6 - Huaxin New Materials' subsidiary received two utility model patent certificates for innovative devices [19] - Lingang Steel's new 2290 cubic meter blast furnace has been successfully put into operation [21] - Xinlitai received drug registration certificate for Sacubitril/Valsartan tablets, the first of its kind in China [23] Group 7 - Aike Co.'s subsidiary received project designation notices from multiple clients for electric drive platform components [25] - Tonghe Pharmaceutical received drug registration certificate for Apixaban in South Korea [26] - Junting Hotel signed a cooperation agreement with Choice Hotels for exclusive brand usage in mainland China [28] Group 8 - Guangdong Hongtu plans to establish a wholly-owned subsidiary in Zhengzhou to enhance market layout [30] - Yuheng Pharmaceutical signed a joint promotion agreement for Pemafibrate tablets with Xinghe Pharmaceutical [31] - Chongqing Steel terminated the absorption and merger of its wholly-owned subsidiary, citing strategic advantages of independent operation [33] Group 9 - Jihong Co. announced the listing of its H-shares on the Hong Kong Stock Exchange [34] - Deshi Co. announced plans for shareholders to reduce their holdings by up to 0.3% [36] - Xinhai Medical's subsidiary received medical device registration for a dialysis fluid filter [42]

Market Overview - On May 27, major market indices continued to decline, with mixed performance among individual stocks, highlighting a focus on sectors such as nuclear power, solid-state batteries, innovative pharmaceuticals, and new consumption [1][2]. High-Performing Stocks - In the nuclear power sector, notable stocks included Zhongchao Holdings with 11 consecutive trading limits over 17 days, Baili Electric with 5 over 8 days, and Hahai Huadong and Rongfa Nuclear Power with 3 consecutive limits [2]. - The chemical fiber sector saw Suzhou Longjie achieving 9 limits over 13 days and Youfu Co. with 6 over 11 days [2]. - IP economy concept stocks like Jinghua Laser and Laishen Tongling both recorded 5 limits over 6 days [2]. Stock Performance Data - Zhongchao Holdings (002471) recorded a price increase of 10.04% with a trading volume of 21.51 million [3]. - Jinghua Laser (603607) saw a price rise of 9.99% with a trading volume of 6.12 million [3]. - Laishen Tongling (603900) also increased by 10.00% with a trading volume of 7.27 million [3]. - Other notable stocks included Huide Technology (603192) with a 10.00% increase and a trading volume of 2.28 million [3]. Top Net Buying Stocks - The top three net buying stocks on the day were Qingdao King (1.77 billion), Fenghuo Electronics (1.43 billion), and Hengtian Hailong (994 million) [4]. - Key stocks with significant net buying included Kaimeite Gas (2.49 billion) and Youfu Co. (1.77 billion) [5]. Institutional Activity - Institutional net buying was significant in stocks like Xinghui Co. (341.30 million) and Qingdao King (268.46 million) [7]. - Conversely, stocks like Xinyuan (476.20 million) and Nuofeng (417.22 million) experienced substantial net selling by institutions [8]. Sector Highlights - The nuclear power sector remains a focal point for investors, with multiple stocks showing strong performance and significant trading activity [2][3]. - The solid-state battery sector is also gaining traction, with stocks like Jinlongyu (002882) showing a 10.01% increase and significant trading volume [5][6]. Conclusion - The market is currently characterized by volatility, with specific sectors like nuclear power and solid-state batteries attracting investor interest, as evidenced by the performance of key stocks and institutional trading patterns [1][2][4].

Core Viewpoint - Shanghai Sailun Biotechnology Co., Ltd. announced its 2024 annual profit distribution plan, which includes a cash dividend of 0.2 RMB per share, totaling 21,644,000 RMB for all shareholders [1][2]. Distribution Plan - The profit distribution plan was approved at the company's annual shareholders' meeting on May 16, 2025 [1]. - The total share capital before the distribution is 108,220,000 shares, with a cash dividend of 0.2 RMB per share (before tax) [1][2]. Relevant Dates - The key dates for the distribution are as follows: - Record date for shareholders: Not specified - Ex-dividend date: Not specified - Cash dividend payment date: Not specified [1]. Implementation Method - Cash dividends for unrestricted circulating shares will be distributed through the China Securities Depository and Clearing Corporation Limited, Shanghai Branch [1]. - Shareholders who have completed designated transactions can receive their cash dividends on the payment date at their designated securities firms [1]. Taxation Information - For individual shareholders holding unrestricted circulating shares: - If the holding period exceeds 1 year, the cash dividend is exempt from individual income tax, resulting in a net payment of 0.2 RMB per share [2][3]. - For holding periods within 1 year, the company will not withhold income tax at the time of distribution, but tax will be calculated based on the holding period when the shares are sold [2][3]. - The actual tax burden varies based on the holding period, with a maximum tax rate of 20% for shares held for 1 month or less [3][4]. - For qualified foreign institutional investors (QFII), a 10% withholding tax applies, resulting in a net payment of 0.18 RMB per share [5]. Contact Information - For inquiries regarding this equity distribution, shareholders can contact the company's board secretary office at 021-64959122 [6].